WO2012176438A1 - Agent sédatif destiné à la vaporisation et à l'inhalation et composition parfumée sédative le contenant - Google Patents

Agent sédatif destiné à la vaporisation et à l'inhalation et composition parfumée sédative le contenant Download PDF

Info

Publication number
WO2012176438A1
WO2012176438A1 PCT/JP2012/003989 JP2012003989W WO2012176438A1 WO 2012176438 A1 WO2012176438 A1 WO 2012176438A1 JP 2012003989 W JP2012003989 W JP 2012003989W WO 2012176438 A1 WO2012176438 A1 WO 2012176438A1
Authority
WO
WIPO (PCT)
Prior art keywords
sedative
application example
methylphenol
methoxy
fragrance
Prior art date
Application number
PCT/JP2012/003989
Other languages
English (en)
Japanese (ja)
Inventor
圭子 森
篤 城市
陽子 合津
信一郎 土師
Original Assignee
株式会社 資生堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 資生堂 filed Critical 株式会社 資生堂
Publication of WO2012176438A1 publication Critical patent/WO2012176438A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B9/00—Essential oils; Perfumes
    • C11B9/0061—Essential oils; Perfumes compounds containing a six-membered aromatic ring not condensed with another ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F1/00—General methods for the manufacture of artificial filaments or the like
    • D01F1/02—Addition of substances to the spinning solution or to the melt
    • D01F1/10—Other agents for modifying properties
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F2/00—Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof
    • D01F2/02—Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof from solutions of cellulose in acids, bases or salts
    • D01F2/04—Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof from solutions of cellulose in acids, bases or salts from cuprammonium solutions

Definitions

  • the present invention relates to a sedative and a sedative fragrance composition containing the same, and more particularly to a sedative that provides a sedative effect by inhaling a vaporized active ingredient.
  • the composition of the fragrance may differ depending on the production area of the natural fragrance, the year of harvest, the method of collecting the fragrance, and the like, and a reproducible and stable effect cannot be expected. There was a problem.
  • Patent Document 1 1,3-dimethoxy-5-methylbenzene
  • Patent Document 2 trialkoxybenzene
  • Patent Document 3 dimethoxybenzene
  • an object of the present invention is to provide a novel sedative for vaporization inhalation that can bring about a sedative effect by vaporization inhalation and is compatible with various fragrances. is there.
  • the sedative for vaporization inhalation of the present invention is characterized by containing 3-methoxy-5-methylphenol as an active ingredient.
  • 3-methoxy-5-methylphenol having a sweet and good scent like phenol or oak moss, it is possible to provide a sedative effect simply and effectively by vaporization inhalation in various modes.
  • the sedative for vaporization inhalation of the present invention may further contain other sedative components such as 1,3-dimethoxy-5-methylbenzene.
  • other sedative components such as 1,3-dimethoxy-5-methylbenzene.
  • the sedative fragrance composition of the present invention is characterized in that the sedative for vaporization inhalation is an active ingredient and the blending amount of 3-methoxy-5-methylphenol is 0.001 to 50% by mass.
  • the sedative for vaporization inhalation of the present invention is preferably 3-methoxy-5-methylphenol, which is a fragrance component such as orchid flower and has a sweet and good fragrance, and is used alone or in combination with other fragrance components.
  • the scent is composed and the mind is calmed down safely and easily by vaporization inhalation, and the irritation and insomnia due to stress can be effectively reduced.
  • the sedative for vaporization inhalation of the present invention contains 3-methoxy-5-methylphenol as an active ingredient.
  • 3-Methoxy-5-methylphenol is an aroma component contained in orchids, oak moss, lichens, mushrooms, etc.
  • Orcinyl 3 (trade name) commercially available from Gibodan Japan Co., Ltd. It can be preferably used in the present invention.
  • the sedative for vaporization inhalation of the present invention may further contain other sedative components that bring about sedation by vaporization inhalation as long as the effect of the present invention can be achieved by containing 3-methoxy-5-methylphenol as an active ingredient.
  • examples of such other sedative ingredients include, but are not limited to, trialkoxybenzenes such as 1,3-dimethoxy-5-methylbenzene and trimethoxybenzene, dimethoxybenzene, and the like, in particular 1,3-dimethoxy- Since 5-methylbenzene does not have a strong fragrance, it is suitable for blending with 3-methoxy-5-methylphenol in the present invention.
  • any other component such as a carrier, a diluent, an auxiliary agent and the like can be included as long as the effects of the present invention are not hindered.
  • the sedative fragrance composition having a desired scent can be prepared by appropriately blending the sedative for vaporization inhalation of the present invention with other general fragrance ingredients.
  • the blending amount of 3-methoxy-5-methylphenol in the fragrance composition may be appropriately determined in consideration of the purpose of use and the like, but is usually 0.001 to 50% by mass, more preferably 0.01 to 30% by mass.
  • the perfume composition of the present invention may be used by inhalation as it is, or may be used by adding to any object.
  • the subject to which the sedative for vaporization inhalation of the present invention or the fragrance composition containing the same is blended is any substance as long as 3-methoxy-5-methylphenol is vaporized and can be blended in an inhalable form. However, it is not limited by the dosage form or product form. Moreover, according to the kind of the target object, you may further include the arbitrary component normally contained in the target object other than the said active ingredient.
  • the product form in which the sedative for vaporization inhalation and the like of the present invention is blended is not limited, but includes cosmetics, pharmaceuticals, quasi-drugs, foods, beverages, and the like. Agents, granules, aerosols, solids, gels and the like.
  • Cosmetics that are one of the particularly preferred embodiments include, but are not limited to, for example, perfume, eau de toilette, eau de cologne, cream, milky lotion, lotion, foundations, powdered white powder, lipstick, soap, shampoo / rinse, body Shampoos, body rinses, body powders, bath agents and the like can be mentioned.
  • any miscellaneous goods such as fragrance, deodorant, aroma candle, incense, stationery, wallet, bag, shoes, etc.
  • any clothing such as underwear, clothes, hats, stockings, socks, etc.
  • the sedative for vaporization inhalation of the invention and the like can be included. You may add the sedative for vaporization inhalation of this invention, etc. to any of those raw materials or products.
  • the blending amount of the sedative for vaporization inhalation of the present invention in the object as described above can be appropriately selected depending on other blending components and applications, etc., and is not particularly limited, but is usually based on the total mass of the object. It is 0.000001% by mass or more, more preferably 0.00001% by mass or more, and further preferably 0.0001% by mass or more.
  • the blending amount of the sedative for vaporization in the cosmetics is not particularly limited, but is in a general concentration range, for example, 0.001 to 50% by mass with respect to the total amount of the cosmetics. be able to.
  • 3-Methoxy-5-methylphenol is sweet, has an animal-like, phenol-like, and oak-like aroma, and is an aroma component contained in orchids, oak moss, lichens, and mushrooms.
  • 2-methoxy-4-methylphenol exhibits sweet and spicy phenol and leather-like odor, and is similarly found in orchids.
  • For 3-methoxy-5-methylphenol use Orcinyl® 3 (trade name) commercially available from Givaudan Japan Co., Ltd., and for 2-methoxy-4-methylphenol use creosol, available from Simrise Inc. It was. The test sample was diluted with ethanol to a concentration of 0.2% for 3-methoxy-5-methylphenol and 0.01% for 2-methoxy-4-methylphenol.
  • CNV Contigent negative fluctuation
  • CNV electroencephalogram has a positive correlation with the arousal level of consciousness, and the effect of fragrance on consciousness level (mental sedation / uplifting effect) can be quantitatively evaluated (Torii S et al: Contingent negative variation (CNV) and the psychological effects of odour.
  • CNV electroencephalogram has a positive correlation with the arousal level of consciousness, and the effect of fragrance on consciousness level (mental sedation / uplifting effect) can be quantitatively evaluated (Torii S et al: Contingent negative variation (CNV) and the psychological effects of odour.
  • CNV Contingent negative variation
  • a platinum electrode is attached to the subject's parietal region (Cz), frontal pole center (Fpz), left ear (A1), and right ear (A2), and the potential difference of Cz ⁇ (A1 + A2) is measured by using an electroencephalograph (Fz) as the ground.
  • Fz electroencephalograph
  • MEB-2216 Nihon Kohden Co., Ltd.
  • the ratio of the CNV early component integrated value ( ⁇ V / s) when the fragrance component is inhaled to the CNV early component integrated value ( ⁇ V / s) when the fragrance component is not inhaled (control) (relative CNV early component integrated value ( %)).
  • the results are shown in FIG. When the relative CNV early component integrated value is larger than 100, there is a wakefulness effect, and when it is smaller than 100, there is a sedative effect.
  • Application Example 2-2 Milk Mass% (1) Ethyl alcohol 10.0 (2) Glycerin 3.0 (3) Butylene glycol 2.0 (4) Polyethylene glycol 3.0 (5) Carboxyvinyl polymer 0.1 (6) Acrylic acid / alkyl acrylate copolymer 0.1 (7) Potassium hydroxide 0.1 (8) Cyclomethicone 4.0 (9) Squalane 2.0 (10) Spherical polyethylene 2.0 (11) Menthol 0.5 (12) Drug 1.0 (13) Paraben 0.1 (14) Edetate trisodium 0.1 (15) Pigment 0.1 (16) Sedative fragrance composition of Application Example 1-2 0.01 (17) Total amount of purified water remaining 100
  • Application Example 2-3 Cream mass% (1) Glycerin 10.0 (2) Butylene glycol 5.0 (3) Carbomer 0.1 (4) Potassium hydroxide 0.2 (5) Stearic acid 2.0 (6) Glyceryl stearate 2.0 (7) Glyceryl isostearate 2.0 (8) Vaseline 5.0 (9) Preservative 0.1 (10) Antioxidant 0.1 (11) Sedative fragrance composition of Application Example 1-1 0.05 (12) Chelating agent 1.0 (13) Pigment 0.01 (14) Stearyl alcohol 2.0 (15) Behenyl alcohol 2.0 (16) Palm hardened oil 2.0 (17) Squalane 10.0 (18) Potassium 4-methoxysalicylate 3.0 (19) Total remaining amount of purified water 100
  • Application Example 2-4 Cream mass% (1) Glycerol 3.0 (2) Dipropylene glycol 7.0 (3) Polyethylene glycol 3.0 (4) Glyceryl stearate 3.0 (5) Glyceryl isostearate 2.0 (6) Stearyl alcohol 2.0 (7) Behenyl alcohol 2.0 (8) Liquid paraffin 7.0 (9) Cyclomethicone 3.0 (10) Dimethicone 1.0 (11) Octyl methoxycinnamate 0.1 (12) Sodium hyaluronate 0.05 (13) Preservative 0.1 (14) Antioxidant 0.1 (15) Sedative fragrance composition of Application Example 1-2 0.05 (16) Chelating agent 1.0 (17) Pigment 0.01 (18) Total amount of purified water remaining 100
  • Application Example 2-5 Gel mass% (1) Ethyl alcohol 10.0 (2) Glycerin 5.0 (3) Butylene glycol 5.0 (4) Carbomer 0.5 (5) Aminomethylpropanol 0.3 (6) Polyethylene glycol-60 hydrogenated castor oil 0.3 (7) Menthol 0.02 (8) Preservative 0.05 (9) Chelating agent 1.0 (10) Sedative fragrance composition of Application Example 1-1 0.01 (11) Total amount of purified water remaining 100
  • Application Example 2-7 Aerosol mass% (1) Alcohol 15.0 (2) Butylene glycol 2.0 (3) Glycerin 1.0 (4) Polypropylene glycol-13 Decyltetrades 24 0.1 (5) Silver supported zeolite 1.0 (6) Chelating agent 1.0 (7) Dye 0.3 (8) Sedative fragrance composition of Application Example 1-2 0.01 (9) Liquefied petroleum gas 40.0 (10) Total amount of purified water remaining 100
  • Application Example 2-9 Shampoo Mass% (1) Lauryl polyoxyethylene (3) Sulfate sodium salt (30% aqueous solution) 30.0 (2) Sodium lauryl sulfate ester salt (30% aqueous solution) 10.0 (3) Palm oil fatty acid diethanolamide 4.0 (4) Glycerin 1.0 (5) Preservative 0.1 (6) Sedative fragrance composition of Application Example 1-2 0.05 (7) Dye 0.1 (8) Metal ion sequestering agent 0.1 (9) pH adjuster 0.5 (10) Total amount of purified water remaining 100
  • Application Example 2-10 Rinse Mass% (1) Silicone oil 3.0 (2) Liquid paraffin 1.0 (3) Cetyl alcohol 1.5 (4) Stearyl alcohol 1.0 (5) Stearyltrimethylammonium chloride 0.7 (6) Glycerin 3.0 (7) Sedative fragrance composition of Application Example 1-1 0.2 (8) Dye 0.1 (9) Preservative 0.05 (10) Total amount of purified water remaining 100
  • Application Example 2-12 Fragrance Weight% (1) Alcohol 75.0 (2) Dipropylene glycol 5.0 (3) Sedative fragrance composition of Application Example 1-2 10.0 (4) Antioxidant 8.0 (5) Dye 0.01 (6) UV absorber 0.01 (7) Total amount of purified water remaining 100
  • Application Example 2-13 Room Fragrance Weight% (1) Alcohol 80.0 (2) Antioxidant 5.0 (3) Sedative fragrance composition of Application Example 1-1 3.0 (4) 3-Methyl-3-methoxybutanol 5.0 (5) Dibenzylidenesorbitol 5.0 (6) Total amount of purified water remaining 100
  • Application Example 2-15 Bath agent mass% (1) Sodium sulfate 45.0 (2) Sodium bicarbonate 45.0 (3) Lavender oil 9.0 (4) Sedative fragrance composition of Application Example 1-1 1.0 Total 100
  • Application Example 2-16 Massage Gel Mass% (1) Erythritol 2.0 (2) Caffeine 5.0 (3) Oat extract 3.0 (4) Glycerin 50.0 (5) Carboxyvinyl polymer 0.4 (6) Polyethylene glycol 400 30.0 (7) edet trisodium 0.1 (8) Polyoxylene (10) Methylpolysiloxane copolymer 2.0 (9) Squalane 1.0 (10) Potassium hydroxide 0.15 (11) Sedative fragrance composition of Application Example 1-2 0.5 (12) Total amount of purified water remaining 100
  • Application Example 2-18 Microcapsules (particles) in which the soothing perfume composition of the present invention is encapsulated in an aromatic fiber cuproammonium cellulose solution (cellulose concentration 10% by mass, ammonium concentration 7% by mass, copper concentration 3.6% by mass) Add 50% by mass or less of 3-methoxy-5-methylphenol to the microcapsule in a range of 0.1 to 20% by mass with respect to the cellulose mass, mix, and then perform normal wet spinning. Spinning was carried out according to the method, and an aromatic fiber was obtained through a refining step and a drying step.
  • an aromatic fiber cuproammonium cellulose solution cellulose concentration 10% by mass, ammonium concentration 7% by mass, copper concentration 3.6% by mass
  • Application Example 2-19 Granule Mass% (1) Sucralose 0.1 (2) Sedative fragrance composition of Application Example 1-1 0.005 (3) Flavoring 5.0 (4) Excipient (Theolus) 10.0 (5) Maltitol total remaining amount 100
  • Application Example 2-20 Tablet (Chewable Type) mass% (1) Inositol 11.0 (2) Maltitol 21.0 (3) Sucrose 0.5 (4) White coconut extract (DNA Na) 0.1 (5) Yeast extract 0.1 (6) Sedative fragrance composition of Application Example 1-1 0.00001 (7) Flavoring 5.0 (8) Total remaining amount of excipient 100
  • Application Example 2-21 Tablet mass% (1) Lubricants (sucrose fatty acid esters, etc.) 1.0 (2) Gum arabic aqueous solution (5%) 2.0 (3) Acidulant 1.0 (4) Coloring agent 0.01 (5) Sedative perfume composition of Application Example 1-2 (6) Sugar (powdered sugar or sorbitol, etc.) Total remaining amount 100
  • Application Example 2-22 Candy Mass% (1) Sugar 50.0 (2) Minamata 47.95 (3) Organic acid 2.0 (4) Sedative fragrance composition of Application Example 1-1 0.0005 Total 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Textile Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Manufacturing & Machinery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)

Abstract

[Problème] Le problème de l'invention réside en la fourniture d'une nouvelle substance qui peut exercer un effet sédatif de manière sûre et efficace par le biais de sa vaporisation et de son inhalation. [Solution] Selon l'invention, un agent sédatif destiné à la vaporisation et à l'inhalation comprend du 3-méthoxy-5-méthylphénol comme principe actif.
PCT/JP2012/003989 2011-06-24 2012-06-19 Agent sédatif destiné à la vaporisation et à l'inhalation et composition parfumée sédative le contenant WO2012176438A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011140302A JP2013006791A (ja) 2011-06-24 2011-06-24 気化吸入用鎮静剤及びそれを含有する鎮静香料組成物
JP2011-140302 2011-06-24

Publications (1)

Publication Number Publication Date
WO2012176438A1 true WO2012176438A1 (fr) 2012-12-27

Family

ID=47422295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/003989 WO2012176438A1 (fr) 2011-06-24 2012-06-19 Agent sédatif destiné à la vaporisation et à l'inhalation et composition parfumée sédative le contenant

Country Status (3)

Country Link
JP (1) JP2013006791A (fr)
TW (1) TW201302189A (fr)
WO (1) WO2012176438A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7279059B2 (ja) * 2018-03-30 2023-05-22 高砂香料工業株式会社 睡眠を改善するためのフレグランス組成物とその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63199292A (ja) * 1987-02-13 1988-08-17 高砂香料工業株式会社 香料組成物及び該香料組成物を含む香粧品
JPH06172781A (ja) * 1992-09-25 1994-06-21 Takasago Internatl Corp 鎮静効果を与える香料改質剤
JP2000086478A (ja) * 1998-09-11 2000-03-28 Shiseido Co Ltd 気化吸引用鎮静剤及びそれを有効成分とする鎮静香料組成物
EP1172118A2 (fr) * 2000-06-23 2002-01-16 INTERNATIONAL FLAVORS & FRAGRANCES INC. Composition à propriétés antimicrobiennes et parfumantes contenant du salicylaldéhyde et procédés pour son utilisation
JP2006290823A (ja) * 2005-04-13 2006-10-26 Shiseido Co Ltd 鎮静効果付与剤及びそれを含有する鎮静香料組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63199292A (ja) * 1987-02-13 1988-08-17 高砂香料工業株式会社 香料組成物及び該香料組成物を含む香粧品
JPH06172781A (ja) * 1992-09-25 1994-06-21 Takasago Internatl Corp 鎮静効果を与える香料改質剤
JP2000086478A (ja) * 1998-09-11 2000-03-28 Shiseido Co Ltd 気化吸引用鎮静剤及びそれを有効成分とする鎮静香料組成物
EP1172118A2 (fr) * 2000-06-23 2002-01-16 INTERNATIONAL FLAVORS & FRAGRANCES INC. Composition à propriétés antimicrobiennes et parfumantes contenant du salicylaldéhyde et procédés pour son utilisation
JP2006290823A (ja) * 2005-04-13 2006-10-26 Shiseido Co Ltd 鎮静効果付与剤及びそれを含有する鎮静香料組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DING, ZHIHUI ET AL.: "Chemical Constituents from Parmelia tinctorum", YUNNAN ZHIWU YANJIU; ACTA BOTANICA YUNNANICA, vol. 12, no. 1, 1990, pages 99 - 106 *
SATOSHI KOGA ET AL.: "Charactarization of Oakmoss absolute", KANZEI CHUO BUNSEKISHO HO; REPORTS OF THE CENTRAL CUSTOMS LABORATORY, vol. 31, 1992, pages 87 - 95 *
SCHULZ, H. ET AL.: "Characterization of Oakmoss Products Used in Perfumery by High- Performance Liquid Chromatography", JOURNAL OF CHROMATOGRAPHY, vol. 466, 1989, pages 301 - 306 *
SHEKHTMAN, N. M. ET AL.: "Organoleptic properties of the Derivatives of Resorcinol", MASLO-ZHIROVAYA PROMYSHLENNOST, 1987, pages 24 - 25 *
SHUCHI-KAN'YO GIJUTSUSHU (KORYO) DAI III-BU KOSHOHIN-YO KORYO, 2001, pages 224 - 229 *
TABACCHI, R. ET AL.: "Contribution to the Knowledge of the Chemical Composition of Oakmoss (Evernia prunastri (L.) Ach.)", VII INTERNATIONAL CONGRESS OF ESSENTIAL OILS, 1979, pages 384 - 387 *

Also Published As

Publication number Publication date
TW201302189A (zh) 2013-01-16
JP2013006791A (ja) 2013-01-10

Similar Documents

Publication Publication Date Title
EP1941870B1 (fr) Composition de parfum contenant du perilla aldehyde
JP3519747B2 (ja) 鎮静効果を与える香料改質剤
EP1875902B1 (fr) Agent sedatif et composition sedative qui le contient liberant une fragrance
BR112016013533B1 (pt) Composição, método para acentuar o perfil de fragrância de uma composição, método para produzir um produto para o consumidor, produto ou artigo de perfumaria para consumidor e método para modificar ou melhorar as propriedades de odor de uma superfície corporal
JP7028805B2 (ja) フレグランス組成物及びその使用の方法
JP2009235015A (ja) 自律神経調整剤
KR102055499B1 (ko) 감국꽃 정유를 유효성분으로 포함하는 뇌파에서 상대적 세타파는 감소시키고 상대적 알파파는 증가시키는 향료 조성물 및 이의 용도
JP5706889B2 (ja) 皮膚温度上昇剤
JP2012012386A (ja) 副交感神経抑制剤、並びにそれを含有する化粧料、食品及び雑貨
JP5851398B2 (ja) 交感神経抑制剤
WO2012176438A1 (fr) Agent sédatif destiné à la vaporisation et à l'inhalation et composition parfumée sédative le contenant
JP6097342B2 (ja) 交感神経活性化剤、並びにそれを含有する交感神経活性化用化粧料及び交感神経活性化用食品
JP2007031347A (ja) 精神鎮静用組成物
JP5721986B2 (ja) 精神鎮静用組成物
WO2011152005A1 (fr) Agent sympatholytique, et produit cosmétique, produit alimentaire et articles divers contenant celui-ci
JP5745805B2 (ja) 鎮静効果付与剤及び鎮静剤並びに２ｒ−テアスピランの使用
JP6033568B2 (ja) 皮脂分泌抑制効果付与剤及びこれを含有する皮脂分泌抑制剤組成物
JP2012107000A (ja) 交感神経活性化剤
JP5306160B2 (ja) 精神鎮静用香料組成物を製造するための特定の香料成分の使用、及び、香料組成物における精神鎮静効果の付与方法
JP2008044910A (ja) プロラクチン濃度調整剤及び調整方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12803238

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12803238

Country of ref document: EP

Kind code of ref document: A1